E. Guillot

发表

The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.

M. Di Marcello, M. Borgarelli, L. Ferasin, 2021, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs

M. Peyrou, E. Guillot, J. Elliott, 2020, Frontiers in Veterinary Science.

Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.

E. Guillot, P. Ovaert, J. Elliott, 2010, Journal of veterinary pharmacology and therapeutics.

DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.

M. Di Marcello, M. Borgarelli, L. Ferasin, 2020, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)

E. Guillot, C. Garelli-Paar, C. Atkins, 2021 .

Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study

E. Guillot, C. Garelli-Paar, M. Oyama, 2020, Journal of veterinary internal medicine.

Comparison of cytologic and histologic evaluations of the conjunctiva in the normal equine eye.

E. Guillot, I. Raymond-Letron, A. Regnier, 2007, Veterinary ophthalmology.

Harnessing the Biology of Canine Intestinal Organoids to Heighten Understanding of Inflammatory Bowel Disease Pathogenesis and Accelerate Drug Discovery: A One Health Approach

J. Mochel, E. Guillot, A. Jergens, 2021, Frontiers in Toxicology.

PARAmETERS IN DOGS wITH mITRAL VALVE DISEASE

E. Guillot, Sylvie Bourrelier, 2011 .

Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine

J. Mochel, E. Guillot, C. Garelli-Paar, 2023, Scientific Reports.

Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST)

E. Guillot, C. Garelli-Paar, C. Atkins, 2021, Journal of veterinary internal medicine.

The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.

E. Guillot, C. Garelli-Paar, M. Cobb, 2017, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

‘The Mercury Challenge’: feline systolic blood pressure in primary care practice – a European survey

E. Guillot, C. Garelli-Paar, A. Sparkes, 2022, Journal of feline medicine and surgery.

Dose–response of benazepril on biomarkers of the classical and alternative pathways of the renin–angiotensin–aldosterone system in dogs

J. Mochel, E. Guillot, Joseph S Smith, 2023, Scientific Reports.

Breakthrough: A First-In-Class Virtual Simulator for Dose Optimization of ACE Inhibitors in Veterinary Cardiology

J. Mochel, E. Guillot, C. Garelli-Paar, 2022, bioRxiv.

Circulating renin‐angiotensin‐aldosterone system activity in cats with systemic hypertension or cardiomyopathy

J. Mochel, E. Guillot, J. Ward, 2022, Journal of veterinary internal medicine.